Eisai’s Rozebalamin® for Injection 25 mg Wins Good Design Award 2024 for Light-Proof Vial Packaging
Eisai Co., Ltd. (Tokyo, CEO: Haruo Naito) announced that its amyotrophic lateral sclerosis (ALS) treatment, Rozebalamin® for Injection 25 mg (mecobalamin), has received the 2024 Good Design Award from the Japan Institute of Design Promotion for its innovative light-proof vial packaging.
Approved in Japan on September 24, 2024, Rozebalamin features mecobalamin, which is sensitive to light. The packaging employs a black print on aluminum-deposited PET to ensure superior light protection while allowing visibility to confirm the solution inside the vial and the needle tip during extraction. The design includes a resealable window for inspection without compromising the light-blocking capabilities, a challenge that was effectively addressed during development.
This packaging was co-developed with IL Pharma Packaging Co., Ltd., with both companies recognized for the award. Eisai prioritizes neurology as a key therapeutic area and is dedicated to meeting the diverse needs of ALS patients and healthcare professionals by providing high-quality, user-friendly treatment options.
